Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 387

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 387
---
 a New CERo warrant will be the same terms and conditions as were applicable
to a CERo warrant immediately prior to the Effective Time. The Company will issue an aggregate of approximately 5.0 million shares
of Class A common stock to the holders of CERo common stock and CERo preferred stock as consideration in the Business Combination.

<div align='center'>F-42

PHOENIX BIOTECH ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2023</div>

Sponsor Support Agreement

In connection with the execution of the Business
Combination Agreement, the Sponsor, as the sole holder of the Class B common stock, and each of the Company’s officers and
directors entered into a support agreement with the Company and CERo (the “Sponsor Support Agreement”). Under the Sponsor
Support Agreement, the Sponsor agreed to vote, at any meeting of the stockholders of the Company and in any action by written consent
of the stockholders of the Company, all of its shares of Class B common stock (together with any other equity securities of the
Company that it holds of record or beneficially, as of the date of the Sponsor Support Agreement, or of which it acquires record or beneficial
ownership after the date thereof, the “Subject Company Shares”) (i) in favor of (a) the Business Combination Agreement
and the transactions contemplated thereby and (b) the other proposals that the Company and CERo agreed in the Business Combination
Agreement shall be submitted at such meeting for approval by the Company’s stockholders (together with the proposal to obtain the
Company Stockholder Approval, the “Required Transaction Proposals”) and (ii) against any proposal that conflicts or
materially impedes or interferes with any Required Transaction Proposals or that would adversely affect or delay the Business Combination.
The Sponsor Support Agreement also prohibits the Sponsor from, among other things and subject to certain exceptions, transferring any
Subject Company Shares held by the Sponsor or taking any action that would have the effect of preventing or materially delaying the Sponsor
from performing its obligations under the Sponsor Support Agreement, until the earlier of the Closing or the termination of the Sponsor
Support Agreement according to its terms. On July 3, 2023, the Sponsor delivered notice of conversion of an aggregate of 4,596,250 shares
of Class B common stock into an equal number of shares of Class A common stock.